- Home
- VNO vs RGEN Comparison
VNO vs RGEN Comparison
Compare VNO & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNO | RGEN |
|---|---|---|
| Founded | 1946 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 8.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VNO | RGEN |
|---|---|---|
| Price | $33.21 | $164.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 10 |
| Target Price | $37.67 | ★ $174.90 |
| AVG Volume (30 Days) | ★ 1.4M | 566.0K |
| Earning Date | 02-09-2026 | 02-19-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.20 | 0.03 |
| Revenue | ★ $1,903,939,000.00 | $707,890,000.00 |
| Revenue This Year | N/A | $17.84 |
| Revenue Next Year | $1.18 | $12.44 |
| P/E Ratio | ★ $7.92 | $5,307.14 |
| Revenue Growth | 1.75 | ★ 11.74 |
| 52 Week Low | $29.68 | $102.97 |
| 52 Week High | $45.37 | $182.52 |
Technical Indicators
Market Signals| Indicator | VNO | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 53.89 |
| Support Level | $33.37 | $161.41 |
| Resistance Level | $33.84 | $167.65 |
| Average True Range (ATR) | 0.74 | 4.48 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 17.46 | 68.63 |
Price Performance
Historical ComparisonAbout VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.